Texas Attor­ney Gen­er­al Ken Pax­ton Sues Pfiz­er and Tris for Pro­vid­ing Adul­ter­at­ed Phar­ma­ceu­ti­cal Drugs to Children

Texas Attor­ney Gen­er­al Ken Pax­ton Sues Pfiz­er and Tris for Pro­vid­ing Adul­ter­at­ed Phar­ma­ceu­ti­cal Drugs to Children

The Office of the Attorney General’s Civil Medicaid Fraud Division has sued Pfizer, Inc., Tris Pharma, Inc. and Tris CEO Ketan Mehta for defrauding the Texas Medicaid program by providing adulterated pharmaceutical drugs to Texas children in violation of the...
read more
Pfizer Own Documents Show COVID-19 Vaccines Contain Potentially Harmful ‘Modified’ RNA, Not mRNA

Pfizer Own Documents Show COVID-19 Vaccines Contain Potentially Harmful ‘Modified’ RNA, Not mRNA

According to Pfizer and BioNTech’s COVID-19 vaccine label in the FDA’s Fact Sheet for Healthcare Providers, each Pfizer vaccine dose for children ages 5 through 11 contains 10 micrograms (mcg) of modRNA, while fully-approved Comirnaty authorized for use in...
read more
FDA approves controversial new Alzheimer’s drug

FDA approves controversial new Alzheimer’s drug

The US Food and Drug Administration (FDA) on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer’s disease. The FDA approval of the drug, Leqembi, also known as lecanemab, comes...
read more
FDA Wants 55 YEARS to Release Vaccine Approval Documents

FDA Wants 55 YEARS to Release Vaccine Approval Documents

In September, 30 scientists and professors filed a lawsuit to force the FDA to release the documents it reviewed to approve the Pfizer COVID vaccine. The scientists want to “settle the ongoing public debate regarding the adequacy of the FDA’s...
read more
AstraZeneca agrees to buy Alexion for $39 billion

AstraZeneca agrees to buy Alexion for $39 billion

AstraZeneca agrees to buy rare disease firm Alexion for $39 billion. Subject to shareholder approval and certain regulatory clearances, the companies expect the deal to close in Q3 2021. The combined company is set to generate ~$500M of recurring run-rate of....
read more
FDA Warns Of ‘Severe Adverse Reactions’ After Vaccine Dose 2

FDA Warns Of ‘Severe Adverse Reactions’ After Vaccine Dose 2

Pfizer and partner BioNTech’s COVID-19 vaccine meets expectations on agency guidance and is enough to spur an agency review, according to staff of the U.S. Food and Drug Administration. The finding is one of several significant new results featured in the ...
read more
Slovakia Aims To Test All 5 Million Citizens In New Approach To Combating Pandemic

Slovakia Aims To Test All 5 Million Citizens In New Approach To Combating Pandemic

After beating the first wave, brave Slovakia is trying to make sure it doesn’t see a second. The small Central European nation of Slovakia, which was one of the last countries in Europe to confirm its first COVID-19 case thanks...
read more
Gilead agrees to acquire Immunomedics for $21 billion

Gilead agrees to acquire Immunomedics for $21 billion

Immunomedics soars 106% after Gilead agrees to acquire the cancer-drug company for $21 billion. Gilead’s proposed $21 billion acquisition of Immunomedics sent shares of the cancer-drug company soaring as much as 106% on Monday. Immunomedics develope...
read more
Sanofi to acquire Principia Biopharma for $3.68 Billion

Sanofi to acquire Principia Biopharma for $3.68 Billion

Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Princ...
read more
Lysol Maker Begs Public Not To Inject Its Cleaning Products After Dangerous Trump Advice

Lysol Maker Begs Public Not To Inject Its Cleaning Products After Dangerous Trump Advice

During last night’s press briefing, President Trump made some dangerous remarks about a new treatment involving ‘sunlight’ and ‘bleaching’ of the lungs to combat the virus. It appeared that during Thursday night’s presser, T...
read more
Ford and 3M Designers Making Respirators Out of F-150 Seat Coolers

Ford and 3M Designers Making Respirators Out of F-150 Seat Coolers

Ford and 3M Designers Go MacGyver, Making Respirators Out of F-150 Seat Coolers, Power Tool Batteries and Pool Supply Hoses. Their creative collaboration combines off-the-shelf components with digital fabrication and ingenuity. To help fight the COVID-19 crisi...
read more
WHO praises China’s ‘strong action’ to quarantine 11mn in Wuhan

WHO praises China’s ‘strong action’ to quarantine 11mn in Wuhan

The World Health Organization (WHO) has commended China’s swift response to a rapidly moving virus gripping the country, but despite a quick-climbing infection tally, the agency is reluctant to classify it a global health threat. “What they are doing is...
read more
Sanofi recalls popular heartburn drug Zantac as FDA investigates probable carcinogen

Sanofi recalls popular heartburn drug Zantac as FDA investigates probable carcinogen

Sanofi said Friday it will recall the widely-used heartburn drug Zantac from stores in the United States and Canada as the drugmaker and Food and Drug Administration investigate a probable carcinogen detected in the drug. The FDA last month said it...
read more
Novartis CEO Narasimhan Defends Company’s Decision to Withhold False Data From the FDA

Novartis CEO Narasimhan Defends Company’s Decision to Withhold False Data From the FDA

Responding to the agency’s stern rebuke, Vas Narasimhan, the company’s executive, tried to reassure investors that Novartis did not intentionally deceive the FDA while seeking approval for its $2.1 million gene therapy. The chief executive of Novartis on W...
read more
Mylan to merge with Pfizer’s Upjohn

Mylan to merge with Pfizer’s Upjohn

Pfizer will combine its off-patent drug business with Mylan. Pfizer shareholders would own 57% of the new company and Mylan’s shareholders would get 43%. The combined company, which will sell Mylan’s EpiPen and Pfizer’s Viagra, will be domiciled in the.....
read more